Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
